Tikvah Management LLC Acquires Shares of 2,460,833 Atyr PHARMA INC (NASDAQ:ATYR)

Tikvah Management LLC acquired a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,460,833 shares of the company’s stock, valued at approximately $8,908,000. Atyr PHARMA comprises about 2.5% of Tikvah Management LLC’s portfolio, making the stock its 15th largest holding. Tikvah Management LLC owned about 2.93% of Atyr PHARMA as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Alterna Wealth Management Inc. purchased a new stake in Atyr PHARMA in the 4th quarter worth approximately $36,000. Victory Capital Management Inc. bought a new stake in Atyr PHARMA in the fourth quarter valued at $37,000. Raymond James Financial Inc. bought a new stake in Atyr PHARMA in the fourth quarter valued at $39,000. ExodusPoint Capital Management LP purchased a new position in Atyr PHARMA during the 4th quarter valued at $61,000. Finally, Farther Finance Advisors LLC bought a new position in Atyr PHARMA in the 4th quarter worth $88,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Atyr PHARMA Stock Performance

Shares of ATYR stock opened at $2.62 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The company has a market capitalization of $232.81 million, a price-to-earnings ratio of -2.79 and a beta of 0.95. Atyr PHARMA INC has a one year low of $1.42 and a one year high of $4.66. The company’s 50-day moving average is $3.57 and its 200 day moving average is $3.21.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. Sell-side analysts expect that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They set an “overweight” rating on the stock. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. Leerink Partners started coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Atyr PHARMA in a research note on Friday, March 14th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Atyr PHARMA has a consensus rating of “Buy” and a consensus target price of $18.60.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.